Search research articles
Contact Us
Filters
Showing results (51-60 of 66) with videos related to
Page
of 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2003
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy
Edward J Licitra, Viral Vyas, Kathy Nelson, et al.
Molecular Cancer Therapeutics
|
June 18, 2011
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach
Janice M Mehnert, Antoinette R Tan, Rebecca Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies
Eric H Rubin, Dinesh P de Alwis, Isabelle Pouliquen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2014
AACR Cancer Progress Report 2014
Carlos L Arteaga, Peter C Adamson, Jeffrey A Engelman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer
Amit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
Patricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Journal of the National Cancer Institute
|
December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Molecular Cancer Therapeutics
|
December 14, 2002
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I
Robert B Lobell, Dongming Liu, Carolyn A Buser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEK
Anthony W Tolcher, Khurum Khan, Michael Ong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
Paul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 66) with videos related to
Sort By:
Page
of 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 10, 2003
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy
Edward J Licitra, Viral Vyas, Kathy Nelson, et al.
Molecular Cancer Therapeutics
|
June 18, 2011
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach
Janice M Mehnert, Antoinette R Tan, Rebecca Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 11, 2002
A phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies
Eric H Rubin, Dinesh P de Alwis, Isabelle Pouliquen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 18, 2014
AACR Cancer Progress Report 2014
Carlos L Arteaga, Peter C Adamson, Jeffrey A Engelman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 3, 2020
A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive <i>TP53</i>-mutant Ovarian Cancer
Amit M Oza, Maria Estevez-Diz, Eva-Maria Grischke, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 11, 2003
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors
Patricia M LoRusso, Roy S Herbst, Danny Rischin, et al.
Journal of the National Cancer Institute
|
December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology
Brian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Molecular Cancer Therapeutics
|
December 14, 2002
Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I
Robert B Lobell, Dongming Liu, Carolyn A Buser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 18, 2014
Antitumor activity in RAS-driven tumors by blocking AKT and MEK
Anthony W Tolcher, Khurum Khan, Michael Ong, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 19, 2018
Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop
Paul G Kluetz, Bindu Kanapuru, Steven Lemery, et al.
Page
of 7